Sign up to save your podcasts
Or
Share Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.
View all episodes
By BiotechTV
4.3
77 ratings
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.
More shows like BiotechTV - News
View all
WSJ What’s News
4,413 Listeners
The a16z Show
1,107 Listeners
The Meb Faber Show - Better Investing
948 Listeners
The Daily
113,475 Listeners
The Readout Loud
336 Listeners
The Intelligence from The Economist
2,569 Listeners
The Prof G Pod with Scott Galloway
5,659 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,233 Listeners
Business Of Biotech
87 Listeners
BioCentury This Week
35 Listeners
Biotech Hangout
21 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
460 Listeners
Prof G Markets
1,476 Listeners
The BioCentury Show
12 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
3 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners